Trinity Biotech Unveils AI-Native CGM+ Wearable Biosensor Platform.

Trinity Biotech has unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform for the $260 billion AI wearables market. The AI-native continuous glucose monitoring system combines multi-sensor data and real-time analytics, featuring a compact wearable and reusable sensor applicator. It integrates an ultra-thin minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature, and physical activity.

Trinity Biotech plc (Nasdaq: TRIB) has unveiled CGM+, an innovative continuous glucose monitoring (CGM) platform designed to target the burgeoning $260 billion AI wearable market. This next-generation wearable biosensor combines multi-sensor data and real-time analytics, integrating glucose monitoring with heart activity, body temperature, and physical activity tracking in a single, compact device [1].

CGM+ features an ultra-thin, minimally invasive electrochemical glucose sensor and proprietary needle-free technology, reducing disposable components and lowering care costs. The platform is engineered to provide a comprehensive view of metabolic and physiological health, offering insights into sleep, stress, and physical activity [1].

The global CGM market is projected to grow from $13.28 billion in 2025 to $28.72 billion by 2030, at a CAGR of 16.68% [1]. Trinity Biotech's CGM+ is positioned to capture a significant share of this high-growth sector, as well as the broader AI in healthcare market, expected to reach approximately $200 billion by 2030 [2].

Trinity Biotech anticipates a commercial launch of CGM+ in mid-2026, targeting both clinical and consumer health markets. The company aims to generate multiple revenue streams, including device sales, AI analytics subscriptions, and strategic partnerships with healthcare providers, insurers, and digital health platforms [1].

The platform's AI-native capabilities position Trinity Biotech to compete in the intersection of chronic disease management, digital health, and consumer wellness. As healthcare shifts toward precision medicine and continuous real-world data collection, CGM+ is poised to become a critical enabler of AI-based diagnostics and behavioral coaching [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/24/3121046/8624/en/Trinity-Biotech-Unveils-CGM-An-AI-Native-Platform-Targeting-the-260-Billion-AI-Wearable-Market.html
[2] https://www.stocktitan.net/news/TRIB/trinity-biotech-unveils-cgm-an-ai-native-platform-targeting-the-260-sgtiep59q74b.html